Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Relevance of NR1I2 variants on carbamazepine therapy in Mexican Mestizos with epilepsy at a tertiary-care hospital.

Pharmacogenomics - 1 Oct 2021

Fricke-Galindo Ingrid, Jung-Cook Helgi, Martínez-Juárez Iris E, Monroy-Jaramillo Nancy, Ortega-Vázquez Alberto, Rojas-Tomé Irma S, Dorado Pedro, Peñas-Lledó Eva, Llerena Adrián, López-López Marisol

Abstract excerpt

Aim: We evaluated the potential influence of genetic (CYP3A5, EPHX1, NR1I2, HNF4A, ABCC2, RALBP1, SCN1A, SCN2A and GABRA1) and nongenetic factors on carbamazepine (CBZ) response, adverse drug reactions and CBZ plasma concentrations in 126 Mexican Mestizos (MM) with epilepsy. Subjects & methods: Patients were genotyped for 27 variants using TaqMan® assays. Results: CBZ response was associated with NR1I2 variants...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticonvulsants
Share to Carbamazepine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epoxide Hydrolases

Share to Lamotrigine

Share to NAV1.1 Voltage-Gated Sodium Channel

Share to Phenytoin

Share to Pregnane X Receptor

Share to Tertiary Care Centers

Source

Identifiers

PMID: 34612084
DOI: 10.2217/pgs-2021-0081

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Relevance of NR1I2 variants on carbamazepine therapy in Mexican Mestizos with epilepsy at a tertiary-care hospital.PMID 34612084Read ↗

Associations between<i>CYP3A4, CYP3A5</i>and<i>SCN1A</i>Polymorphisms and Carbamazepine Metabolism in Epilepsy: A Meta-analysisSemantic proximity Read ↗

Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization.Semantic proximity Read ↗

Pharmacogenetics of Carbamazepine: A Systematic Review on CYP3A4 and CYP3A5 Polymorphisms.Semantic proximity Read ↗

Polymorphic Variants of SCN1A and EPHX1 Influence Plasma Carbamazepine Concentration, Metabolism and Pharmacoresistance in a Population of Kosovar Albanian Epileptic Patients.Semantic proximity Read ↗

Association of xenobiotic receptor polymorphisms with carbamazepine response in epilepsy patients.Semantic proximity Read ↗

Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy.Semantic proximity Read ↗

Associations between CYP3A4, CYP3A5 and SCN1A polymorphisms and carbamazepine metabolism in epilepsy: A meta-analysis.Semantic proximity Read ↗

Effects of EPHX1 and CYP3A4*22 genetic polymorphisms on carbamazepine metabolism and drug response among Tunisian epileptic patients.Semantic proximity Read ↗

Pharmacogenetic variants of CYP2C9 and CYP2C19 associated with adverse reactions induced by antiepileptic drugs used in PeruSemantic proximity Read ↗

The clinical impact of pharmacogenetics on the treatment of epilepsy.Semantic proximity Read ↗

Association between EPHX1 polymorphisms and carbamazepine metabolism in epilepsy: a meta-analysis.Semantic proximity Read ↗

ABCB1 c.3435C > T and EPHX1 c.416A > G polymorphisms influence plasma carbamazepine concentration, metabolism, and pharmacoresistance in epileptic patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.